Zophtal

Each mL contains: Brinzolamide 10 mg.
Preservative: Benzalkonium Chloride 0.01%.

Pharmacology: Carbonic anhydrase (CA) is an enzyme which is found in many tissues of the body including the eye. It catalyzes the reversible reaction involving the hydration of carbon dioxide and the dehydration of carbonic acid. In humans, carbonic anhydrase exists as a number of isoenzymes, the most active being carbonic anhydrase II (CA-II), found primarily in red blood cells (RBCs), but also in other tissues. Inhibition of carbonic anhydrase in the ciliary processes of the eye decreases aqueous humor secretion, presumably by slowing the formation of bicarbonate ions with subsequent reduction in sodium and fluid transport. The result is a reduction in intraocular pressure (IOP).
Brinzolamide, an inhibitor of carbonic anhydrase II (CAII). Following topical ocular administration, Brinzolamide inhibits aqueous humor formation and reduces elevated intraocular pressure. Elevated intraocular pressure is a major risk factor in the pathogenesis of optic nerve damage and glaucomatous visual field loss.
Following topical ocular administration, Brinzolamide is absorbed into the systemic circulation. Due to its affinity for CA-II, Brinzolamide distributes extensively into the RBCs and exhibits a long half-life in whole blood (approximately 111 days). In humans, the metabolite N-desethyl Brinzolamide is formed, which also binds to CA and accumulates in RBCs. This metabolite binds mainly to CA-I in the presence of Brinzolamide. In plasma, both parent Brinzolamide and N-desethyl Brinzolamide concentrations are low and generally below assay quantitation limits (< 10 ng/mL). Binding to plasma proteins is approximately 60%. Brinzolamide is eliminated predominantly in the urine as unchanged drug. N-Desethyl Brinzolamide is also found in the urine along with lower concentrations of the N-desmethoxypropyl and O-desmethyl metabolites.
Oral pharmacokinetic study was conducted in which healthy volunteers received 1 mg capsules of Brinzolamide twice per day for up to 32 weeks. This regimen approximates the amount of drug delivered by topical ocular administration of Brinzolamide ophthalmic suspension 1% dosed to both eyes three times per day and simulates systemic drug and metabolite concentrations similar to those achieved with long-term topical dosing. RBC CA activity was measured to assess the degree of systemic CA inhibition. Brinzolamide saturation of RBCCA-II was achieved within 4 weeks (RBC concentrations of approximately 20 (μM). N-Desethyl Brinzolamide accumulated in RBCs to steady-state within 20-28 weeks reaching concentrations of 20 (μM). N-Desethyl Brinzolamide accumulated in RBCs to steady-state within 20-28 weeks reaching concentrations ranging from 6-30. The inhibition of CA-II activity at steady-state was approximately 70-75%, which is below the degree of inhibition expected to have a pharmacological effect on renal function or respiration in healthy subjects.
In a clinical study brinzolamide ophthalmic suspension 1% dosed three times per day (TID) in patient with elevated intraocular pressure (IOP), produced significant reductions in IOPs (4-5 mmHg). These IOP reductions are equivalent to the reductions observed with Dorzolamide Hydrochloride ophthalmic solution 2% dosed TID in the same studies.
In clinical study patient with elevated intraocular pressure, Brinzolamide ophthalmic suspension 1% was associated with less stinging and burning upon instillation than Dorzolamide Hydrochloride 2% ophthalmic solution.

ZOPHTAL Sterile Eye Drops Suspension is indicated for the treatment of elevated Intraocular Pressure (IOP) in patients with ocular hypertension or open-angle glaucoma.

The recommended dose is 1 drop of ZOPHTAL (Brinzolamide ophthalmic suspension) 1% in the affected eye(s) three times daily.
ZOPHTAL (Brinzolamide ophthalmic suspension) 1% may be used concomitantly with other topical ophthalmic drug products to lower intraocular pressure. If more than one topical ophthalmic drug is being used, the drugs should be administered at least ten minutes apart.

Although no human data are available, electrolyte imbalance, development of an acidotic state, and possible nervous system effects may occur following oral administration. Serum electrolyte levels (particularly potassium) and blood pH levels should be monitored.

ZOPHTAL is contraindicated in patients who are hypersensitive to any component of this product.

Benzalkonium Chloride, which is commonly used as preservative in ophthalmic products, has been reported to cause punctate keratopathy and/or toxic ulcerative keratopathy. Since this drug contains Benzalkonium Chloride, close monitoring is required in frequent or prolonged use in dry eye patients, or in conditions where the cornea is compromised.
Contact lenses: Patients should be advised not to wear contact lenses if their eye is red. This drug should not be used to treat contact lenses-related irritation. The preservative in this drug, Benzalkonium Chloride, may be absorbed by soft contact lenses. Patients who wear soft contact lenses and whose eyes are not red should be instructed to wait at least 10 minutes after instilling this drug before they insert their contact lenses.
ZOPHTAL is a sulfonamide and although administered topically it is absorbed systemically. Therefore, the same types of adverse reactions that are attributable to sulfonamides may occur with topical administration of ZOPHTAL. Fatalities have occurred, although rarely, due to severe reactions to sulfonamides including Stevens-Johnson syndrome, toxic epidermal necrolysis, fulminant hepatic necrosis, agranulocytosis, aplastic anemia, and other blood dyscrasias. Sensitization may recur when a sulfonamide is re-administered irrespective of the route of administration. If signs of serious reactions or hypersensitivity occur, discontinue the use of this preparation.

General: Carbonic anhydrase activity has been observed in both the cytoplasm and around the plasma membranes of the corneal endothelium. The effect of continued administration of ZOPHTAL on the corneal endothelium has not been fully evaluated. The management of patients with acute-closure glaucoma requires therapeutic interventions in addition to ocular hypotensive agents. ZOPHTAL has not been studied in patients with acute angle-closure glaucoma. ZOPHTAL has not been studied in patients with severe renal impairment (CrCl < 30 mL/min). Because ZOPHTAL and its metabolite are excreted predominantly by the kidney. ZOPHTAL is not recommended in such patients.
ZOPHTAL has not been studied in patients with hepatic impairment and should be used with caution in such patients.
There is a potential for an additive effect on the known systemic effects of carbonic anhydrase inhibition in patients receiving an oral carbonic anhydrase inhibitor and ZOPHTAL. The concomitant administration of ZOPHTAL and oral carbonic anhydrase inhibitors is not recommended.
Information for Patients: ZOPHTAL (Brinzolamide ophthalmic suspension) 1% is a sulfonamide and although administered topically, it is absorbed systemically; therefore, the same types of adverse reactions attributable to sulfonamides may occur with topical administration.
Patients should be advised that if serious or unusual ocular or systemic reactions or signs of hypersensitivity occur, they should discontinue the use of the product and consult their physician (see Warnings).
Vision may be temporarily blurred following dosing with ZOPHTAL (Brinzolamide ophthalmic suspension) 1%. Care should be exercised in operating machinery or driving a motor vehicle.
Patient should be instructed to avoid allowing the tip of the dispensing container to contact the eye or surrounding structures or other surfaces, since the product can become contaminated by common bacteria known to cause ocular infections. Serious damage to the eye and subsequent loss of vision may result from using contaminated solutions.
Patient should also be advised that if they have ocular surgery or develop an intercurrent ocular condition (e.g. trauma or infection), they should immediately seek their physician's advice concerning the continued use of the present multidose container.
If more than one topical ophthalmic drug is being used, the drugs should be administered at least ten minutes apart. The preservative in ZOPHTAL (Brinzolamide ophthalmic suspension) 1%, benzalkonium chloride, may be absorbed by soft contact lenses. Contact lenses should be removed during instillation of ZOPHTAL (Brinzolamide ophthalmic suspension) 1%, but may be reinserted 15 minutes after instillation.
Pediatric Use: A three-month controlled clinical study was conducted in which ZOPHTAL (Brinzolamide ophthalmic suspension) 1% was dosed only twice a day in pediatric patients 4 weeks to 5 years of age. Patients were not required to discontinue their IOP-lowering medication(s) until initiation of monotherapy with ZOPHTAL. IOP lowering efficacy was not demonstrated in this study in which the mean decrease in elevated IOP was between 0 and 2 mmHg. Five out of 32 patients demonstrated an increase in corneal diameter of one millimeter.
Geriatric Use: No overall differences in safety or effectiveness have been observed between elderly and younger patients.

Pregnancy: Teratogenic Effect: Pregnancy Category C. Developmental toxicity studies with Brinzolamide in rabbits at oral doses of 1, 3, and 6 mg/kg/day (20, 62, and 125 times the recommended human ophthalmic dose) produced maternal toxicity at 6 mg/kg/day and a significant increase in the number of fetal variations, such as accessory skull bones, which was only slightly higher than the historic value at 1 and 6 mg/kg. In rats, statistically decreased body weights of fetuses from dams receiving oral doses of 18 mg/kg/day (375 times the recommended human ophthalmic dose) during gestation were proportional to the reduced maternal weight gain, with no statistically significant effects on organ or tissue development. Increases in unossified sternebrae, reduced ossification of the skull, and unossified hyoid that occurred at 6 and 18 mg/kg were not statistically significant. No treatment-related malformations were seen. Following oral administration of l4C-Brinzolamide to pregnant rats, radioactivity was found to cross the placenta and was present in the fetal tissues and blood.
There are no adequate and well-controlled studies in pregnant women. ZOPHTAL (Brinzolamide ophthalmic suspension) 1% should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.
Nursing Mothers: In offspring at an oral dose of 15 mg/kg/day (312 times the recommended human ophthalmic dose) were seen during lactation. No other effects were observed. However, following oral administration of 14C-Brinzolamide to lactating rats, radioactivity was found in milk at concentrations below those in the blood and plasma.
It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants from ZOPHTAL (Brinzolamide ophthalmic suspension) 1%, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.

The most frequently reported adverse events associated with ZOPHTAL were blurred vision and bitter, sour or unusual taste. Blepharitis, dermatitis, dry eye, foreign body sensation, headache, hyperemia, ocular discharge, ocular discomfort, ocular keratitis, ocular pain, ocular pruritus and rhinitis were reported at a rare incidence.
The following adverse reactions were reported at a very rare incidence: allergic reactions, alopecia, chest pain, conjunctivitis, diarrhea, diplopia, dizziness, dry mouth, dyspnea, dyspepsia, eye fatigue, hypertonia, keratoconjunctivitis, keratopathy, kidney pain, lid margin crusting or sticky sensation, nausea, pharyngitis, tearing and urticaria.

ZOPHTAL Sterile Eye Drops Suspension contains a carbonic anhydrase inhibitors. Acid-base and electrolyte alterations were not reported in the clinical trials with brinzolamide. However, in patients treated with oral carbonic anhydrase inhibitors, rare instances of acid-base alterations have occurred with high-dose salicylate therapy. Therefore, the potential for such drug interactions should be considered in patients receiving ZOPHTAL.
Carcinogenesis, Mutagenesis, Impairment of Fertility: Carcinogenicity data on Brinzolamide are not available. The following tests for mutagenic potential were negative: (1) in vivo mouse micronucleus assay; (2) in vivo sister chromatid exchange assay; and (3) Ames E. coli test. The in vitro mouse lymphoma forward mutation assay was negative in the absence of activation, but positive in the presence of microsomal activation. In reproduction studies of Brinzolamide in rats, there were no adverse effects on the fertility or reproductive capacity of males or females at doses up to 18 mg/kg/day (375 times the recommended human ophthalmic dose).

Shake well before use.
Use within 4 weeks after opening.

Store below 30°C.

Antiglaucoma Preparations

S01EC04 - brinzolamide ; Belongs to the class of carbonic anhydrase inhibitors. Used in the treatment of glaucoma.

K